Patient-Derived 3D Brain Tumor Models for Clinically Relevant Drug Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current in vitro brain tumor models, particularly those for pediatric brain tumors, lack clinical relevance due to genetic and phenotypic differences from actual tumors, limited availability of primary cells, and inadequate representation of brain-specific microenvironmental factors, making it difficult to assess drug responses and tumor progression accurately.
Innovation Solution
Development of patient-derived 3D brain tumor models using silk protein scaffolds coated with extracellular matrix and endothelial cells, replicating the in vivo microenvironment, allowing for the assessment of drug responses and tumor behavior.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If existing brain tumor cell lines are used, then model availability is improved, but clinical relevance deteriorates due to genetic and phenotypic differences from actual tumors
Solution Approach 1:
The patent creates 3D tumor spheroids that are direct copies of patient tumors, preserving the original tumor's genetic and phenotypic characteristics. These spheroids are generated from patient tumor tissue using a standardized protocol that maintains the authentic tumor architecture and molecular profile, thereby ensuring clinical relevance while providing abundant model material.
Solution Approach 2:
The patent transforms 2D cell cultures into 3D spheroid structures, fundamentally changing the spatial arrangement parameter. This dimensional transition restores the microenvironmental context lost in traditional cell lines, enabling the preservation of authentic tumor characteristics including cell-cell interactions, extracellular matrix contact, and physiological signaling that define clinical relevance.
2Reliability
If primary cells from pediatric brain tumors are used, then clinical relevance is improved, but cell availability deteriorates due to limited samples and uncertain viability
Solution Approach 1:
The patent performs preliminary processing of patient tumor tissue immediately after surgical resection, creating 3D spheroids before the tissue degrades or becomes unavailable. This time-sensitive preliminary action preserves the authentic tumor characteristics while maximizing the utility of limited primary samples, as the spheroids can be generated from small tissue amounts that would otherwise be insufficient.
Solution Approach 2:
The patent recovers and preserves authentic tumor characteristics by creating permanent 3D spheroid models from limited primary tissue samples. Once the spheroids are generated, they serve as stable, replicable models that can be stored and reused, effectively recovering the value of the limited primary cells for multiple research applications.
3Ease of manufacture
If traditional 2D cell culture models are used, then ease of manufacture is improved, but representation of brain-specific microenvironmental factors deteriorates
Solution Approach 1:
The patent transitions from 2D monolayer cultures to 3D spheroid structures, adding the spatial dimension that is critical for representing the brain microenvironment. This dimensional change enables the incorporation of extracellular matrix contact, cell-cell interactions in three dimensions, and gradient formations (oxygen, nutrients, waste) that are essential for authentic brain tumor biology.
Solution Approach 2:
The patent creates composite 3D spheroid structures that integrate tumor cells with brain-specific extracellular matrix components and vasculature. These composite models replicate the multi-component nature of the brain microenvironment, including pericytes, astrocytes, and neuropil, thereby achieving both manufacturability and biological fidelity.
4Quantity of substance
If adult brain tumor cell lines are used, then model availability is improved, but accuracy in assessing pediatric tumor responses deteriorates
Solution Approach 1:
The patent generates 3D spheroids from pediatric patient tumors, creating models with local quality specific to each patient's tumor type and molecular profile. This approach preserves the unique characteristics of pediatric tumors (such as medulloblastoma, ependymoma, astrocytoma subtypes) rather than using generic adult cell lines, thereby achieving high measurement precision for assessing pediatric tumor responses to therapies.
Data Source
AI summary
Described herein is a method for assessing an effect of an agent on a brain tumor sample which includes contacting a personalized in vitro brain tumor model with the agent; and assessing an effect of the agent on the personalized in vitro brain tumor model. The personalized in vitro brain tumor model can include a culture medium and patient tumor cells, wherein a brain tumor tissue sample is extracted directly from the patient, dissociated, and the patient tumor cells from the brain tumor tissue sample seeded directly onto a three-dimensional solid scaffold in the absence of extracellular matrix or endothelial cells to provide tumor growth on the scaffold, wherein the three-dimensional solid scaffold includes a biocompatible and/or biodegradable material, wherein the three-dimensional solid scaffold and directly seeded patient tumor cells are optionally coated with extracellular matrix and/or endothelial cells.